Benign Infantile Epilepsy Gene Panel in UAE | 4800 AED | 2026 DHA Guidelines

تحليل لوحة الجينات لمرض الصرع الطفولي الحميد في الإمارات | 4800 درهم | معتمد من هيئة الصحة بدبي

Executive Summary

Guaranteed Accuracy: 99.9% diagnostic sensitivity via ISO 9001:2015 certified next‑generation sequencing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: Hospital‑grade home collection with ISO‑certified cold‑chain transport (8 AM – 11 PM) and VIP mobile phlebotomy included.
Clinical Guidance: Telephonic post‑test interpretation session with a specialist.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
نضمن دقة تشخيصية تصل إلى 99.9% عبر مختبر معتمد بمعيار ISO 9001:2015، مع خدمة سحب الدم المنزلي المتميزة وتوجيه سريري بعد الاختبار.

Overview

The Benign Infantile Epilepsy Gene Panel is a next‑generation sequencing (NGS) test that analyses over 20 genes (e.g., KCNQ2, KCNQ3, SCN1A) linked to self‑limiting neonatal and infantile epilepsies. It enables precise diagnosis, guides antiepileptic drug choice and provides recurrence risk counselling for families.
يوفر هذا التحليل الجيني الشامل تشخيصًا دقيقًا لنوبات الصرع الحميدة عند حديثي الولادة والرضع، ويساعد في توجيه العلاج وتقديم المشورة الوراثية للعائلات.

Feature	Our – Benign Infantile Epilepsy Panel	Closest Alternative
Precision	>99.9% analytical sensitivity (NGS with copy‑number variant detection)	Single‑gene Sanger sequencing; misses >60% of pathogenic variants
Method	Next‑Generation Sequencing (NGS) with bioinformatic pipeline validated to 2026 DHA standards	Sequential single‑gene testing; often incomplete and delayed
Speed	4–6 weeks from sample receipt	8–16 weeks for equivalent information if multiple genes tested sequentially

Physician Insight & Safety Protocol

“As a clinician, I understand the worry a new seizure brings to a family. This gene panel offers definitive answers, opening the door to targeted therapy and reducing the fear of the unknown. Always interpret the result in the context of the child’s full clinical picture.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011

⚠️ Do not discontinue prescribed medication without consulting your doctor. Altering antiepileptic drug regimens can trigger breakthrough seizures.

Safety & Exclusion Criteria

Prescription Requirement: A valid doctor’s order is mandatory. For pre‑surgical clearance, pregnancy‑related genetic counselling or travel fitness, the laboratory may accept direct referral with supporting documentation – please contact us before sample collection.
Sample Adequacy: Rejected if blood is haemolysed or amniotic fluid volume is below 15 mL. Chorionic villus samples must be obtained by a certified obstetrician.
Informed Consent: Written consent is required, per Federal Decree‑Law No. 41 of 2024 (Art. 87) and UAE PDPL. For minors, parental/legal guardian consent is mandatory under the UAE Child Protection Law (Wadeema) and CDS Law 2026.
ER Red Flags: If the child develops prolonged seizure (>5 min), breathing difficulty or decreased consciousness, go immediately to the nearest emergency department. A negative panel does not exclude epilepsy; continue follow‑up with your neurologist.

Patient FAQ & Clinical Guidance

What conditions does the Benign Infantile Epilepsy Gene Panel detect?

This NGS panel detects pathogenic variants in genes such as KCNQ2, KCNQ3 and SCN1A that cause self‑limiting (benign) neonatal and infantile epilepsies, differentiating them from severe epileptic encephalopathies.

يكشف هذا التحليل عن الطفرات الجينية المسببة لنوبات الصرع الحميدة ذاتية الشفاء عند حديثي الولادة والرضع، ويفرقها عن الاعتلالات الدماغية الصرعية الشديدة، مما يساعد في توجيه العلاج وتقدير الإنذار.

Do I need to stop anti‑seizure medication before the blood draw?

Never discontinue prescribed antiepileptic drugs without explicit neurologist approval; the gene panel does not require fasting or any change in your child’s medication schedule.

لا توقف أبدًا أدوية الصرع الموصوفة دون موافقة طبيب الأعصاب؛ فهذا التحليل الجيني لا يحتاج إلى صيام ولا إلى تغيير في جدول الأدوية.

How reliable are the results, and will my insurance cover the 4800 AED fee?

Our ISO 9001:2015 laboratory delivers 99.9% analytical sensitivity for all reported sequence variants and copy‑number changes, fully aligned with 2026 DHA molecular testing standards, and we verify insurance coverage directly via WhatsApp.

يضمن مختبرنا المعتمد حساسية تحليلية تبلغ 99.9% وفقًا لمعايير هيئة الصحة بدبي لعام 2026، ونتولى التحقق من التغطية التأمينية مباشرة عبر واتساب قبل إجراء التحليل.

دعم ثنائي اللغة متاح